[{"data":1,"prerenderedAt":237},["ShallowReactive",2],{"$f38e2t7iobpfob":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":21,"top_modalities":52,"top_diseases":78,"top_companies":109,"key_results":136,"trends":197,"previous_editions":206,"comparison":210,"highlighted_classes":236},1,"era-2026","ERA","era","ERA Congress 2026",2026,"Nephrology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},2164,750,143,{"Phase 1":17,"Phase 1\u002F2":4,"Phase 2":18,"Phase 2\u002F3":19,"Phase 3":20},6,20,2,29,[22,26,28,31,34,38,40,44,48,50],{"name":23,"count":24,"share":25},"CD20",52,7,{"name":27,"count":24,"share":25},"TNFSF13",{"name":29,"count":30,"share":25},"BAFF",49,{"name":32,"count":33,"share":17},"GR",44,{"name":35,"count":36,"share":37},"MR",39,5,{"name":39,"count":36,"share":37},"SGLT2",{"name":41,"count":42,"share":43},"C5",27,4,{"name":45,"count":46,"share":47},"AVPR1A",21,3,{"name":49,"count":46,"share":47},"AVPR2",{"name":51,"count":18,"share":47},"CN",[53,57,61,65,67,69,72,75],{"name":54,"count":55,"share":56},"Small molecules",514,69,{"name":58,"count":59,"share":60},"Monoclonal antibodies",184,25,{"name":62,"count":63,"share":64},"Non-antibody therapeutic proteins",75,10,{"name":66,"count":36,"share":37},"Peptides",{"name":68,"count":60,"share":47},"Carbohydrate, lipid and polymer therapeutics",{"name":70,"count":71,"share":19},"Oligonucleotide and RNA therapeutics",16,{"name":73,"count":74,"share":19},"Blood, tissue and cell-derived products",12,{"name":76,"count":77,"share":4},"Natural-product mixtures and botanicals",8,[79,83,87,90,93,96,99,101,103,106],{"name":80,"count":81,"share":82},"chronic kidney disease (CKD)",253,34,{"name":84,"count":85,"share":86},"acute kidney failure (AKF)",97,13,{"name":88,"count":89,"share":86},"IgA nephropathy (IgAN)",96,{"name":91,"count":92,"share":64},"end-stage kidney disease (ESKD)",73,{"name":94,"count":95,"share":17},"kidney allograft rejection",45,{"name":97,"count":98,"share":17},"diabetic glomerulosclerosis",42,{"name":100,"count":98,"share":17},"type 2 diabetes mellitus (T2DM)",{"name":102,"count":82,"share":37},"nephrosis",{"name":104,"count":105,"share":43},"lupus nephritis (LN)",33,{"name":107,"count":108,"share":43},"anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)",28,[110,113,116,119,121,123,125,128,131,134],{"name":111,"count":112,"share":25},"AstraZeneca",53,{"name":114,"count":115,"share":25},"Bayer",50,{"name":117,"count":118,"share":17},"Genentech",46,{"name":120,"count":33,"share":17},"RemeGen",{"name":122,"count":20,"share":43},"Amgen",{"name":124,"count":108,"share":43},"Novartis",{"name":126,"count":127,"share":47},"Pfizer",24,{"name":129,"count":130,"share":47},"Alexion Pharmaceuticals",23,{"name":132,"count":133,"share":47},"Bristol Myers Squibb",22,{"name":135,"count":46,"share":47},"Roche",[137,145,153,160,167,173,181,189],{"title":138,"drug":139,"company":141,"phase":142,"disease":102,"finding":143,"url":144},"The Use of Rituximab In the treatment of Nephrotic Glomerulonephritis (TURING): a multicentre, double-blind, randomised, placebo-controlled trial",{"name":140,"slug":140},"rituximab",null,"Phase 3","The efficacy of rituximab treatment was observed for both MCD (HR=0.23, 95% CI 0.12-0.43; p\u003C0.0001) and FSGS patients (HR=0.23, 95% CI 0.085-0.60; p=0.0027).","https:\u002F\u002Fera-distribution.m-anage.com\u002Ffrom.storage?image=t-ie-XUh6bCwB-ViVysHv9DZdMgMqhCnyu8tg04QvRIuobhqUox-_xpTPf4YXshu0",{"title":146,"drug":147,"company":141,"phase":142,"disease":150,"finding":151,"url":152},"Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial",{"name":148,"slug":149},"polymyxin B","polymyxin-b","septic shock","At 28 days, 41 (39%) patients in the polymyxin B group and 23 (45%) in the control group had died, yielding a posterior probability of benefit of 95·3% (APACHE-II adjusted odds ratio 0·67 [95% credible interval 0·39–1·08]).","https:\u002F\u002Fera-distribution.m-anage.com\u002Ffrom.storage?image=t-ie-XUh6bCwB-ViVysHv0kK8__qbV5PuBWTyzSLLmlIjGO4GgyY1o4FRu6563QF0",{"title":154,"drug":155,"company":114,"phase":142,"disease":157,"finding":158,"url":159},"Finerenone in patients with glomerulonephritis",{"name":156,"slug":156},"finerenone","Glomerulonephritis (GN)","The composite kidney-cardiovascular endpoint occurred in 65 vs 78 participants in the finerenone and placebo arms, respectively (HR 0.81; 95% CI 0.58, 1.13; p=0.214).","https:\u002F\u002Fera-distribution.m-anage.com\u002Ffrom.storage?image=t-ie-XUh6bCwB-ViVysHv4eJRHDXjkhBoziexQPaPCfjuPilMBdYo_246sZhogaW0",{"title":161,"drug":162,"company":124,"phase":142,"disease":88,"finding":165,"url":166},"Iptacopan achieves near-normal kidney function decline in prespecified IgA nephropathy (IgAN) patient subgroups: APPLAUSE-IgAN final data",{"name":163,"slug":164},"Iptacopan","iptacopan","At any time up to M24, 118\u002F238 (49.6%) and 65\u002F238 (27.3%) pts on iptacopan and 55\u002F239 (23.0%) and 19\u002F239 (7.9%) on pbo had UPCR from first morning void \u003C0.5 (HR 2.66 [95% CI 1.92, 3.67]) and \u003C0.3 g\u002Fg (HR 3.75 [95% CI 2.24, 6.25]), respectively (post hoc).","https:\u002F\u002Fera-distribution.m-anage.com\u002Ffrom.storage?image=t-ie-XUh6bCwB-ViVysHvzBqj2zokuOPe7ePEcbiZwOrFypDYlAq13bubXlXDGeJ0",{"title":168,"drug":169,"company":124,"phase":142,"disease":88,"finding":171,"url":172},"Efficacy and safety of atrasentan treatment in participants with IgA nephropathy: 2.5-year eGFR results from the ALIGN trial",{"name":170,"slug":170},"atrasentan","Fluid retention AEs occurred in 24 (14.2%) vs 20 (11.8%) participants in the atrasentan and placebo groups, respectively, in the main stratum, and 3 (9.4%) vs 2 (6.3%) participants, respectively, in the SGLT2i stratum.","https:\u002F\u002Fera-distribution.m-anage.com\u002Ffrom.storage?image=t-ie-XUh6bCwB-ViVysHv9cOBihBFsIbrAz-VL6XtwqzG7edS_NZ76bp5s-qoiV-0",{"title":174,"drug":175,"company":177,"phase":178,"disease":88,"finding":179,"url":180},"Efficacy and safety of HSK39297, a once-daily oral CFB inhibitor, in patients with primary IgA nephropathy: a double-blind phase II trial",{"name":176,"slug":176},"ciprocopan","Haisco Pharmaceutical Group","Phase 2","The most common TEAEs (incidence≥5%) were upper respiratory tract infection (13.6% vs. 0% for placebo) and hyperlipidemia (7.6% vs. 4.8%).","https:\u002F\u002Fera-distribution.m-anage.com\u002Ffrom.storage?image=t-ie-XUh6bCwB-ViVysHv6rkZ-0FrdhFNpGLTOj9uqh9746U9OCIsqtc_nR8gxMX0",{"title":182,"drug":183,"company":114,"phase":178,"disease":80,"finding":187,"url":188},"Effect of Nurandociguat on Albuminuria in Patients with CKD: A Phase 2, Randomized Dose-Finding Clinical Trial",{"name":184,"slug":185,"named_as":186},"BAY3283142","bay3283142","Nurandociguat","Symptomatic hypotension, an AE of special interest, occurred in 10.7% of participants in the pooled nurandociguat arms (2.5 mg: 5.6%;5 mg: 5.6%;10 mg: 10.3%; 15 mg: 11.3%; 20 mg: 20.6%; placebo: 1.6%).","https:\u002F\u002Fera-distribution.m-anage.com\u002Ffrom.storage?image=t-ie-XUh6bCwB-ViVysHv6XZCPa52n8FK9bwIq7wBRGpq5r5ommo14g0oL55uN-S0",{"title":190,"drug":191,"company":193,"phase":178,"disease":194,"finding":195,"url":196},"Zilebesiran as Add-on Treatment to RAAS Inhibitors for Patients with Hypertension: Data From KARDIA-2 and KARDIA-3 Phase 2 Trials",{"name":192,"slug":192},"zilebesiran","Alnylam Pharmaceuticals","hypertension (HTN)","Adverse events occurred in 54.1% and 47.6% of patients in the zilebesiran and placebo groups, respectively.","https:\u002F\u002Fera-distribution.m-anage.com\u002Ffrom.storage?image=t-ie-XUh6bCwB-ViVysHv2JMV9WPHulYf3H8efqdWRyyeCy3hYrePreK9ho6l73Q0",{"summary":198,"bullets":200},[199],"Monoclonal antibodies accounted for 25% of drug-linked abstracts, up from 19% in 2025. BAFF accounted for 7% of drug-linked abstracts, up from 3% in 2025. Natural-product mixtures and botanicals (1%) were new to the top modalities compared with 2025.",[201,202,203,204,205],"AVPR1A (3% of drug-linked abstracts) and AVPR2 (3%) were new to the top targets compared with 2025.","Small molecules were the most frequent modality (69%).","CD20 and TNFSF13 were the most frequent targets (7% each).","Chronic kidney disease (CKD) was the most frequent disease (34%).","AstraZeneca had the largest company share (7%).",[207],{"year":208,"abstracts":209},2025,1885,{"previous_year":208,"abstracts":211,"targets":214,"modalities":227,"new_in_top_targets":234,"new_in_top_modalities":235},{"previous":209,"current":13,"change_pct":212,"direction":213},15,"rose",[215,217,219,220,223,225],{"name":29,"count":30,"share":25,"previous_count":216,"previous_share":47,"direction":213},19,{"name":27,"count":24,"share":25,"previous_count":218,"previous_share":47,"direction":213},17,{"name":45,"count":46,"share":47,"previous_count":47,"previous_share":4,"direction":213},{"name":39,"count":36,"share":37,"previous_count":221,"previous_share":77,"direction":222},43,"fell",{"name":224,"count":64,"share":4,"previous_count":212,"previous_share":47,"direction":222},"EGLN1",{"name":226,"count":64,"share":4,"previous_count":71,"previous_share":47,"direction":222},"PHD1",[228,230,232],{"name":58,"count":59,"share":60,"previous_count":229,"previous_share":216,"direction":213},109,{"name":62,"count":63,"share":64,"previous_count":231,"previous_share":17,"direction":213},35,{"name":233,"count":25,"share":4,"previous_count":71,"previous_share":47,"direction":222},"Non-radioactive imaging and contrast agents",[45,49],[76],[],1793970603087]